Clinical trials: Epithelial Cancer Patients
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body…
- Conditions
- Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma
- Trial name
- NCT00365157
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Cancer Institute (NCI)
Brain Cancer, Malignant Glioma
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
The purpose of this study is to test the safety of a new plan for treating glioblastoma. The usual first treatment for glioblastoma is to give focused radiation over 6 weeks in combination with a chemotherapy called temozolomide.
- Trial name
- NCT00782756
- Testing
- radiotherapy (RT) in combination with temozolomide and bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme, Astrocytoma
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.
- Trial name
- NCT00154375
- Testing
- Imatinib mesylate, Hydroxyurea
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003102
- Testing
- Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Cancer
Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer
Studying samples of blood and tissue in the laboratory from patients with a high risk of developing ovarian cancer may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00699907
- Testing
- flutamide
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Arizona
Intrahepatic Cholangiocarcinoma
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in…
- Trial name
- SIRCCA (NCT02807181)
- Testing
- Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 89 people
- Sponsor
- Sirtex Medical
Neuroblastoma
Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone…
- Trial name
- NCT02924324
- Testing
- propofol, ropivacaine, Wong-Baker FACES® Pain Rating Scale
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Pancreatic Cancer
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with…
- Trial name
- NCT01088815
- Testing
- Gemcitabine, nab-Paclitaxel, GDC-0449
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma (HCC)
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local…
- Trial name
- NCT03753659
- Testing
- Pembrolizumab, Radio Frequency Ablation (RFA), Microwave Ablation (MWA)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer, Carcinoma
Molecular Profiling in Lung Cancer Patients
The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in…
- Trial name
- NCT00191308
- Testing
- pemetrexed, cisplatin, Radical Non-Small Cell Lung Cancer (NSCLC) surgery
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Squamous Non-Small-Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
- Trial name
- NCT00152477
- Testing
- Carboplatin, Paclitaxel, CDP791 10mg/kg
- Where
- 21 sites in Hungary, Poland and 1 more
- Volunteers
- 165 people
- Sponsor
- UCB Pharma
Transitional Cell Carcinoma, Bladder Carcinoma
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
- Conditions
- Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
- Trial name
- NCT01215136
- Testing
- Everolimus, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Matthew Galsky
Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer.
- Trial name
- NCT02784171
- Testing
- Cisplatin, Pemetrexed, Pembrolizumab
- Where
- 57 sites in Canada, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Canadian Cancer Trials Group
Lung Cancer
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00828009
- Testing
- bevacizumab, Tecemotide, carboplatin
- Where
- 88 sites in United States
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Basal Cell Nevus Syndrome, Gorlin's Syndrome
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).
- Trial name
- Vismodegib (NCT01556009)
- Testing
- Vismodegib, Aminolevulinic acid %20 topical solution
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Head and Neck Squamous Cell Carcinoma
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The investigators hypothesize that inhibition of angiogenesis and PD-1 will be more effective than inhibition of PD-1 alone. The first step in pursuing proof of this hypothesis is to establish the safety and feasibility of…
- Trial name
- NCT03650764
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03684811
- Testing
- FT-2102, Azacitidine, Nivolumab
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- Forma Therapeutics, Inc.
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Pazopanib in Treating Patients With Recurrent Glioblastoma
This phase II trial is studying the side effects and how well pazopanib works in treating patients with recurrent glioblastoma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00459381
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.